Ayako Makino; Jason X. J. Yuan.
Ambrisentan: A New Drug for Pulmonary Arterial Hypertension, AccessMedicinePulmonary arterial hypertension (PAH) is a rare, progressive and life-threatening condition that affects approximately 100,000 people in the United States. The FDA has approved ambrisentan (LETAIRIS) for the once-daily treatment of PAH to improve exercise capacity and delay clinical worsening.